MHRA Issues Drug Alert for Emerade Adrenaline Auto-Injector Device

News
Article

MHRA has issued a drug alert for the Emerade adrenaline auto-injector device, as a result of the device’s potential to fail in delivery of the dose due to blockage of the needle.

The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has issued a drug alert for the Emerade adrenaline auto-injector device, as a result of the device’s potential to fail in delivery of the dose due to blockage of the needle.

In an alert, published July 11, 2019, the agency revealed that Bausch & Lomb UK, the company that markets the device, had highlighted a risk of the device failing to deliver a dose of adrenaline due to needle blockage in June 2018. However, as it was deemed then to only affect 1.5 in every 10 thousand devices it was considered a rare event.

Recent information, however, has highlighted that the potential for needle blockage is higher than originally estimated and so the issue has been brought to the attention of the patients. Now, it is estimated that 2.3 pens in every thousand may be effected, which has been based on simulated laboratory conditions without the auto-injector component.

Current recommendations are to carry two pens at all times in cases where a patient does not improve after first injection, which is a possibility for numerous reasons other than device failure. The agency reports that if patients continue to follow the recommendations to carry two pens the risk of not being able to deliver a dose of adrenaline is significantly reduced.

The MHRA’s alert is in force for Emerade devices of all strengths and does not apply to other marketed brands of adrenaline auto-injectors. However, the agency is not recalling any batches of Emerade.

Source: MHRA

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content